Trials / Active Not Recruiting
Active Not RecruitingNCT04706715
LAG3 PET Imaging in Advanced Solid Tumors
ImmunoPET Imaging With 89Zr-DFO-REGN3767 in Patients With Advanced Solid Cancer Prior to and During Treatment With Cemiplimab With or Without Platinum-based Chemotherapy
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- University Medical Center Groningen · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an investigator-initiated, single-center, open-label clinical trial designed to evaluate the safety and PK of the PET tracer 89Zr-DFO-REGN3767 in patients prior to and during treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | 89Zr-DFO-REGN3767 | Anti-LAG-3 PET imaging tracer |
| DRUG | Cemiplimab | Cemiplimab 350 mg every 3 weeks with or without platinum-based chemotherapy. |
Timeline
- Start date
- 2022-01-18
- Primary completion
- 2025-11-01
- Completion
- 2025-11-01
- First posted
- 2021-01-13
- Last updated
- 2025-05-31
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT04706715. Inclusion in this directory is not an endorsement.